TuHURA Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
39.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.50next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly6.3MTarget: Sufficient to fund operations beyond anticipated top-line Phase 3 data
Research and Development (R&D) Expenses Quarterly5.2MTarget: Budgeted clinical trial expenditures
Watch Items
- Phase 3 IFx-2.0 Merkel Cell Carcinoma (MCC) Trial EnrollmentTrigger: Complete enrollment expected in 2H 2027Action: Monitor clinical site activation and patient recruitment rates
- TBS-2025 Phase 1b/2 Trial Initiation in mutNPM1 r/r AMLTrigger: Initiation planned for 2H 2026Action: Track FDA feedback on IND and development plan
- Credit Facility DrawdownsTrigger: Drawdowns on the $50 million revolving credit facility with Parkview Holdings One LLCAction: Monitor monthly cash burn and interest expense under the 12% annual rate
Research as of 19 Jun 2026